发现,优化和生物活性评估基尼衍生物作为潜在的KRAS G12D抑制剂
Ran Sun1, Yangfan Hu1, Xiangwen Liu1
1School of Pharmaceutical Sciences, Shanghai Jiao Tong University, No. 800 Dongchuan Rd. Minhang District, Shanghai 200240, PR China.
Bioorganic chemistry
|May 23, 2024
概括
新的基尼衍生物在对抗KRAS G12D突变癌症方面表现有前途. 在临床前模型中,一种化合物SK12有效地减少了瘤生长,并诱导了癌细胞死亡.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 克拉斯G12D突变是各种癌症的关键驱动因素,对治疗提出了重大挑战.
- 开发针对KRAS G12D的向抑制剂对于有效的癌症治疗至关重要.
研究的目的:
- 设计和合成新型基尼衍生物作为KRAS G12D的潜在抑制剂.
- 评估这些衍生物的抗癌活性和作用机制,特别是化合物SK12.
主要方法:
- 基尼衍生物的合成.
- 针对KRAS G12D突变细胞系的体外抗增殖试验 (CT26,A427).
- 亡诱导,反应性氧物种 (ROS) 测量,西部抹杀和表面等离子体共振 (SPR) 试验.
- 在裸体小鼠瘤模型中的体内疗效研究.
主要成果:
- 七种化合物显示出显著的抗增殖作用 (IC50:7.069.21μM) 和抑制了殖民地形成.
- 化合物SK12诱导了亡和瘤细胞中的ROS水平升高.
- SK12调节了KRAS信号通路,抑制了下游蛋白质酸化.
- SPR证实了SK12与KRAS G12D (KD: 157μM) 的结合.
- SK12在体内表现出显著的抗癌疗效 (T/C: 31.04%),具有良好的安全性.
结论:
- 基尼衍生物是KRAS G12D突变癌细胞的有效抑制剂.
- 化合物SK12通过诱导亡和ROS升高表现出强烈的抗癌活性.
- 在KRAS G12D驱动的癌症中,SK12是有前途的治疗候选者.
相关概念视频
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


